Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation

Ki vehet részt

• Age ≥ 18
• Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA
• NIHSS score ≥ 6 obtained prior to endovascular treatment
• Modified Rankin Scale ≤ 1 prior to qualifying stroke
• Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time).with reaching the goal of mTICI grade 2b-3
• For patients with symptom onset within 6 hours: ASPECTS ≥ 3; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3
• Patient/Legally Authorized Representative has signed the Informed Consent Form

Ki nem vehet részt

• Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery
• Current participation in another investigational drug or device study
• Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy
• Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics
• Severe infection (e.g. sepsis) or multiple organ failure
• Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure>185 mmHg or diastolic blood pressure>110 mmHg)
• Malignant brain tumor or CNS infection
• Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)
• local skin damage or other conditions that cannot cooperate with electrode sticking
• severe agitation or other conditions affecting data collection
• Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; oral anticoagulant therapy with INR > 3; or use of a factor Xa inhibitor within the preceding 48 hours with an abnormal aPTT
• Baseline platelet count < 50 × 10\^9/L
• Blood glucose concentration<50 mg/dL (2.7 mmol/L) or >400 mg/dL (22.2 mmol/L)
• Severe cardiomyopathy with heart failure (LVEF ≤ 30% or NYHA class IV), acute myocardial infarction, or unstable angina
• Current hemodialysis or peritoneal dialysis; known severe renal insufficiency with estimated glomerular filtration rate < 30 mL/min or serum creatinine > 220 μmol/L (2.5 mg/dL)
• Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes
• Baseline CT/MRI confirms the presence of arterial dissection
• Known intracranial aneurysm, and cerebral arteriovenous malformation
• Female who is pregnant or lactating at time of admission
• Anticipated life expectancy < 6 months